-
公开(公告)号：US20110076232A1
公开(公告)日：2011-03-31
申请号：US12890029
申请日：2010-09-24
申请人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Achim Jungbluth , Elizabeth Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Gerd Ritter
发明人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Achim Jungbluth , Elizabeth Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Gerd Ritter
IPC分类号： A61K51/10 , C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2863 , A61K39/39558 , A61K51/103 , A61K51/1045 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/30 , C07K16/4266 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译： 本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。
-
公开(公告)号：US20120183471A1
公开(公告)日：2012-07-19
申请号：US13201061
申请日：2010-02-17
申请人： Lloyd J. Old , Constance Old , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elisabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Terrance Grant Johns , Con Panousis , Christoph Renner
发明人： Lloyd J. Old , Constance Old , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elisabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Terrance Grant Johns , Con Panousis , Christoph Renner
IPC分类号： A61K39/395 , A61P35/00 , C12N1/19 , G01N33/574 , C12N5/10 , C12N1/21 , C07K16/30 , A61K51/00
CPC分类号： C07K16/40 , A61K31/495 , A61K39/39541 , A61K39/39558 , A61K47/6871 , A61K51/103 , A61K51/1045 , A61K51/1078 , A61K2039/505 , A61K2300/00 , C07K16/2863 , C07K16/30 , C07K16/4258 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译： 本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。
-
公开(公告)号：US20110293511A1
公开(公告)日：2011-12-01
申请号：US13078781
申请日：2011-04-01
申请人： Terrance Grant Johns , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elizabeth Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Lloyd J. Old , Edward B. Reilly , Andrew C. Phillips , Jonathan A. Meulbroek , Fritz G. Buchanan , Stephen Stockert
发明人： Terrance Grant Johns , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elizabeth Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Lloyd J. Old , Edward B. Reilly , Andrew C. Phillips , Jonathan A. Meulbroek , Fritz G. Buchanan , Stephen Stockert
IPC分类号： A61K39/395 , A61K38/21 , A61K38/20 , A61K103/20 , A61K103/40 , A61K103/30 , A61K103/32 , A61K103/00 , A61P35/00
CPC分类号： C07K16/4266 , A61K39/39558 , A61K51/103 , A61K51/1045 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
-
公开(公告)号：US20110313230A1
公开(公告)日：2011-12-22
申请号：US13078764
申请日：2011-04-01
申请人： Terrance Grant Johns , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elizabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Lloyd J. Old , Edward B. Reilly , Andrew C. Phillips , Jonathan A. Meulbroek , Fritz G. Buchanan
发明人： Terrance Grant Johns , Andrew Mark Scott , Gerd Ritter , Achim Jungbluth , Elizabeth Stockert , Stephen Stockert , Vincent Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice , Anne Murray , George Mark , Lloyd J. Old , Edward B. Reilly , Andrew C. Phillips , Jonathan A. Meulbroek , Fritz G. Buchanan
CPC分类号： A61K39/3955 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K51/103 , A61K51/1045 , A61K51/1078 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2863 , C07K16/30 , C07K16/4241 , C07K16/4258 , C07K16/4266 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/90 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译： 本发明涉及在过表达EGFR的肿瘤细胞上结合EGFR的特异性结合成员，特别是抗体及其片段，以及表达EGFR受体截短型de2-7EGF的肿瘤细胞。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。
-
公开(公告)号：US07589180B2
公开(公告)日：2009-09-15
申请号：US10145598
申请日：2002-05-13
申请人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Gerd Ritter , Achim Jungbluth , Elisabeth Stockert , Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice
发明人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Gerd Ritter , Achim Jungbluth , Elisabeth Stockert , Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , A61K39/395 , A61K39/39541 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/732 , C07K2317/734 , C07K2317/77 , A61K2300/00
摘要： The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.
-
公开(公告)号：US20090137782A1
公开(公告)日：2009-05-28
申请号：US10145598
申请日：2002-05-13
申请人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Gerd Ritter , Achim Jungbluth , Elisabeth Stockert , V. Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice
发明人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Gerd Ritter , Achim Jungbluth , Elisabeth Stockert , V. Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice
IPC分类号： C07K16/30
CPC分类号： C07K16/2863 , A61K39/395 , A61K39/39541 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/732 , C07K2317/734 , C07K2317/77 , A61K2300/00
摘要： The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.
摘要翻译： 本发明涉及特异性结合成员，特别是抗体及其活性片段，其识别异常翻译后修饰，特别是EGFR的异常糖基化形式。 本发明的结合成员，特别是抗体及其片段在正常细胞上不与野生型基因扩增结合，并且能够以不同于 连接肽。 这种抗体的例子是其VH和VL序列如SEQ ID NO：2和4以及其嵌合抗体如ch806所示的新抗体806。
-
公开(公告)号：US20090220510A1
公开(公告)日：2009-09-03
申请号：US12317683
申请日：2008-12-23
申请人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Gred Ritter , Achim Jungbluth , Elisabeth Stockert , V. Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice
发明人： Lloyd J. Old , Terrance Grant Johns , Con Panousis , Andrew Mark Scott , Christoph Renner , Gred Ritter , Achim Jungbluth , Elisabeth Stockert , V. Peter Collins , Webster K. Cavenee , Huei-Jen Su Huang , Antony Wilks Burgess , Edouard Collins Nice
IPC分类号： A61K39/395 , C07K16/18 , C12N15/11 , C12P21/00 , G01N33/574 , C12N1/21 , C12N1/19 , C12N5/06 , C12N5/04
CPC分类号： C07K16/2863 , A61K39/395 , A61K39/39541 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/732 , C07K2317/734 , C07K2317/77 , A61K2300/00
摘要： The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.
摘要翻译： 本发明涉及特异性结合成员，特别是抗体及其活性片段，其识别异常翻译后修饰，特别是EGFR的异常糖基化形式。 本发明的结合成员，特别是抗体及其片段在正常细胞上不与野生型基因扩增结合，并且能够以不同于 连接肽。 这种抗体的例子是其VH和VL序列如SEQ ID NO：2和4以及其嵌合抗体如ch806所示的新抗体806。
-
公开(公告)号：US08652473B2
公开(公告)日：2014-02-18
申请号：US12657919
申请日：2010-01-29
申请人： Terrance Grant Johns , Andrew Mark Scott , Antony Wilks Burgess , Lloyd J. Old , Timothy E. Adams , K. Dane Wittrup , Ginger Chao , Peter Anthony Hoyne
发明人： Terrance Grant Johns , Andrew Mark Scott , Antony Wilks Burgess , Lloyd J. Old , Timothy E. Adams , K. Dane Wittrup , Ginger Chao , Peter Anthony Hoyne
IPC分类号： A61K39/395 , C12P21/08 , C07K16/00
摘要： The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.
摘要翻译： 本发明一般涉及生长因子受体表位肽，特别是EGF家族受体表位肽。 本发明还涉及受体肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明还涉及特异性针对受体肽的抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。
-
公开(公告)号：US07767792B2
公开(公告)日：2010-08-03
申请号：US11060646
申请日：2005-02-17
申请人： Terrance Grant Johns , Andrew Mark Scott , Antony Wilks Burgess , Lloyd J. Old , Timothy E. Adams , K. Dane Wittrup , Ginger Chao , Peter Anthony Hoyne
发明人： Terrance Grant Johns , Andrew Mark Scott , Antony Wilks Burgess , Lloyd J. Old , Timothy E. Adams , K. Dane Wittrup , Ginger Chao , Peter Anthony Hoyne
摘要： The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.
摘要翻译： 本发明一般涉及生长因子受体表位肽，特别是EGF家族受体表位肽。 本发明还涉及受体肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明还涉及特异性针对受体肽的抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。
-
公开(公告)号：US20100322937A1
公开(公告)日：2010-12-23
申请号：US12657919
申请日：2010-01-29
申请人： Terrance Grant Johns , Andrew Mark Scott , Antony Wilks Burgess , Lloyd J. Old , Timothy E. Adams , K. Dane Wittrup , Ginger Chao , Peter Anthony Hoyne
发明人： Terrance Grant Johns , Andrew Mark Scott , Antony Wilks Burgess , Lloyd J. Old , Timothy E. Adams , K. Dane Wittrup , Ginger Chao , Peter Anthony Hoyne
IPC分类号： A61K39/395 , C07K16/00 , A61P35/00
摘要： The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.
摘要翻译： 本发明一般涉及生长因子受体表位肽，特别是EGF家族受体表位肽。 本发明还涉及受体肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明还涉及特异性针对受体肽的抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.077 秒)
